Milants C, Benmouna K, Wang FC (2017) iMAX: a new tool to assess peripheral motor axonal hypoexcitability. Clin Neurophysiol 128(12):2382–2383 DOI: 10.1016/j.clinph.2017.09.111
Uncini A, Susuki K, Yuki N (2013) Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 124(10):1928–1934 DOI: 10.1016/j.clinph.2013.03.025
Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3):387–392 DOI: 10.1002/mus.10559
Heide R, Bostock H, Ventzel L, Grafe P, Bergmans J, Fuglsang-Frederiksen A, Finnerup NB, Tankisi H (2018) Axonal excitability changes and acute symptoms of oxaliplatin treatment: in vivo evidence for slowed sodium channel inactivation. Clin Neurophysiol 129:694–706 DOI: 10.1016/j.clinph.2017.11.015
Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP (2013) Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity. Cancer 119:3570–3577 DOI: 10.1002/cncr.28234
Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, Toyka KV, Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (2001) Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 56(6):758–765 DOI: 10.1212/WNL.56.6.758
Christodoulou C, Anastasopoulos D, Visvikis A, Mellou S, Detsi I, Tsiakalos G, Pateli A, Klouvas G, Papadimitriou A, Skarlos DV (2004) Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy. Anti-Cancer Drugs 15(10):997–999 DOI: 10.1097/00001813-200411000-00010
Jaso R, Sierre M, Calleja J, Valero C, Pascual J (2010) Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association? J Neurol 257(3):488–489 DOI: 10.1007/s00415-009-5400-3
